 |
|
| Blog results | Results 1 - 10 of about 23,255 for sibutramine fda. (0.44 seconds) |
| Sorted by relevance Sort by date |
| 23 Nov 2009 The European Medicines Agency (EMEA) says it has started a review of sibutramine-containing anti-obesity medicines (marketed in Europe under trade names such as Reductil, Zelium, Reduxade), because preliminary data suggest a possible ... thepharmaletter.com - http://www.thepharmaletter.com/ |
| 19 Nov 2009 FDA notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, ... Drugs.com - FDA MedWatch Alerts - http://www.drugs.com/fda_alerts.html - References [ More results from Drugs.com - FDA MedWatch Alerts ] |
| 21 Nov 2009 FDA MedWatch - Meridia (sibutramine): Early Communication about cardiovascular events. foodconsumer.org - http://www.foodconsumer.org/newsite/ [ More results from foodconsumer.org ] |
| 23 Nov 2009 The FDA has notified healthcare professionals and patients that it is reviewing preliminary data from a recent study suggesting that patients using sibutramine (Meridia, from Abbott) have a higher number of cardiovascular events than ... Latest articles from MPR - http://www.empr.com/ [ More results from Latest articles from MPR ] |
| 23 Nov 2009 by pillscribe The FDA said early findings from a recent study suggested patients taking Meridia, also known as sibutramine, may have a higher number of cardiovascular-related problems, including heart attacks, strokes, cardiac arrests and deaths, ... DWS Pill Scribe - http://www.dancewithshadows.com/pillscribe/ - References |
| 23 Nov 2009 Rockville, MD - The FDA is alerting patients and providers about an apparent jump in cardiovascular events among patients taking sibutramine (Meridia, Abbott Laboratories) for weight loss in a preliminary analysis from a randomized ... theHeart.org - http://www.theheart.org/ [ More results from theHeart.org ] |
| 28 Nov 2009 by Kate Traynor BETHESDA, MD 23 November 2009—Preliminary data from a placebo-controlled, 10000-patient study suggest that the antiobesity drug sibutramine may increase patients' risk of cardiovascular adverse events, FDA announced on Friday. ... ASHP Health-System Pharmacy News - http://www.ashp.org/Import/NEWS/HealthSystemPharmacyNews.aspx |
| 21 Nov 2009 by salud equitativa The analysis of these data is ongoing and FDA is making no conclusions about the preliminary findings at this time. These findings highlight the importance of avoiding the use of sibutramine in patients with a history of coronary artery ... CIENCIASMEDICASNEWS - http://elbiruniblogspotcom.blogspot.com/ |
| 23 Nov 2009 by dscheurer The FDA recommends patients with a history of CAD, CHF, CVA, or arrythmias not be prescribed sibutramine (FDA site). This entry was posted on Monday, November 23rd, 2009 at 1:07 pm and is filed under Cardiology. ... Hospital Medicine Quick Hits - http://blogs.hospitalmedicine.org/SHMClinicalBlog/ - References |
| 23 Nov 2009 "While the FDA's analysis is ongoing and the FDA is making no conclusions about the preliminary findings at this time, the FDA's Meridia findings highlight the importance of avoiding the use of sibutramine in patients with a history of ... Kentucky Injury Lawyer Blog - http://www.kentuckyinjurylawyerblog.com/ |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
